TNFRSF17 and hematologic disorder: To date, six products targeting either CD19 or B-cell maturation antigen (BCMA) have been approved in the U.S. (Cappell and Kochenderfer, 2023), with a large number of ongoing trials evaluating additional candidates targeting both hematological malignancies and solid tumors (Wang et al., 2023).